Evolving Landscape of Biologic Therapy for Pediatric Psoriasis

Dermatol Clin. 2024 Jul;42(3):377-386. doi: 10.1016/j.det.2024.02.003. Epub 2024 Mar 27.

Abstract

Pediatric psoriasis is a chronic inflammatory skin condition. Current treatment modalities include topical medications, phototherapy, and systemic drugs, including biological agents. In cases of moderate-to-severe psoriasis recalcitrant to other therapies, biological therapies are often an attractive option given their dosing schedules, safety profiles, and need for less frequent laboratory monitoring, when compared with traditional systemic therapies. This article reviews biological treatment options approved for pediatric psoriasis and identifies others actively under investigation.

Keywords: Biologic therapy; Biologics; Pediatric psoriasis; Psoriasis.

Publication types

  • Review

MeSH terms

  • Adalimumab* / therapeutic use
  • Alefacept
  • Antibodies, Monoclonal / therapeutic use
  • Antibodies, Monoclonal, Humanized / therapeutic use
  • Biological Products* / therapeutic use
  • Biological Therapy
  • Certolizumab Pegol / therapeutic use
  • Child
  • Dermatologic Agents* / therapeutic use
  • Etanercept / therapeutic use
  • Humans
  • Infliximab / therapeutic use
  • Interleukin 1 Receptor Antagonist Protein / therapeutic use
  • Psoriasis* / drug therapy
  • Psoriasis* / therapy
  • Rituximab / therapeutic use
  • Ustekinumab* / therapeutic use

Substances

  • Adalimumab
  • Biological Products
  • Ustekinumab
  • Dermatologic Agents
  • Infliximab
  • Antibodies, Monoclonal, Humanized
  • Etanercept
  • Antibodies, Monoclonal
  • secukinumab
  • guselkumab
  • tocilizumab
  • ixekizumab
  • tildrakizumab
  • risankizumab
  • Rituximab
  • Interleukin 1 Receptor Antagonist Protein
  • Alefacept
  • Certolizumab Pegol